Endo
Hypertension in Diabetes Mellitus
search
Hypertension in Diabetes Mellitus
, Diabetes Mellitus Associated Hypertension
See Also
Diabetes Mellitus
Hypertension
Hypertension Management
Nonpharmacologic Management of Hypertension
DASH Diet
Coronary Artery Disease Prevention in Diabetes
Hyperlipidemia in Diabetes Mellitus
Antiplatelet Management in Diabetes Mellitus
Diabetes Mellitus
Type I Diabetes Mellitus
Type II Diabetes Mellitus
Insulin Resistance Syndrome
Glucose Metabolism
Diabetes Mellitus Education
Diabetes Mellitus Complications
Diabetic Ketoacidosis
Hyperosmolar Hyperglycemic State
Diabetes Mellitus Control in Hospital
Diabetes Mellitus Glucose Management
Hypertension in Diabetes Mellitus
Hyperlipidemia in Diabetes Mellitus
Diabetic Retinopathy
Diabetic Nephropathy
Diabetic Neuropathy
Management
Blood Pressure
Goal
Continue adding agents until goal reached (2 or 3 at a time are the norm)
Small differences in
Blood Pressure
(5 mmHg) have large impact on outcomes
Adults:
Hypertension
goals parallel those for known cardiovascular disease
Blood Pressure
target goals are volatile and differ between organizations
ACC/AHA Guidelines are back to <130/80 mmHg for all patients
ADA Guidelines are up to <140/90 mmHg unless criteria met for 130/80 (see below)
ADA
Blood Pressure
goals have been raised to <140/90
Systolic
Blood Pressure
(SBP) <140 mmHg rationale (compared with intensive group <120 mmHg)
Increased adverse effects (e.g.
Hypotension
,
Hypokalemia
) with intensive SBP lowering
Cardiovascular events were NOT reduced with intensive SBP lowering
Exception: CVA risk was reduced with intensive SBP lowering
Number Needed to Treat
: 89 for 5 years to prevent one CVA
Diastolic
Blood Pressure
(DBP) <80 mmHg rationale
Improved cardiovascular outcomes compared with DBP cutoff of 90
However ADA returned to goal of <90 diastolic as of 2017
Summary of goal
Blood Pressure
s in
Diabetes Mellitus
Indications for BP <130/80 (per ADA), whereas this is the goal for all patients per ACC/AHA
Diabetic Nephropathy
Increased
Cerebrovascular Accident
Risk
See
Cerebrovascular Accident Risk Factors
Younger patients with
Diabetes Mellitus
Longer exposure to pressure burden
Better tolerate lower
Blood Pressure
Diabetes Mellitus
and meeting BP <130/80 goals without adverse effects
Indications for BP <140/90 (per ADA) or <130/80 (per ACC/AHA)
Diabetes Mellitus
without other indications
Negotiate
Blood Pressure
goals with patient
Balance potential benefits (cardiovascular event,
Renal Function
) with risks (e.g.
Hypotension
,
Hypokalemia
)
References
(2018) Presc Lett 25(5):26-7
(2013) Diabetes Care January 36(suppl 1): S11-S66
http://care.diabetesjournals.org/content/36/Supplement_1/S11.full.pdf
Child: Average <95th percentile based on height, gender and age
See
Pediatric Hypertension
See
Hypertension Criteria
NIH Information on
Hypertension in Children
http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf
Complications
Hypertension
adverse effects in
Diabetes Mellitus
Microvascular Complications
Renal Insufficiency
(and
Proteinuria
)
ACE Inhibitor
s beneficial (except renal stenosis)
Calcium Channel Blocker
s beneficial
Angiotensin Receptor Blocker
s beneficial
Autonomic Neuropathy
(e.g.
Impotence
)
Diabetic Retinopathy
Macrovascular Complications
Coronary Artery Disease
ACE Inhibitor
s beneficial
Thiazide Diuretic
s beneficial
Long-acting
Calcium Channel Blocker
s beneficial
Nondihydropyridines (e.g.
Verapamil
) clearly are beneficial
Mixed data on
Dihydropyridine
s
Beta Blocker
s beneficial
Cerebrovascular Disease
ACE Inhibitor
s beneficial
Thiazide Diuretic
s beneficial
Peripheral Vascular Disease
Management
Medications
First-Line Agents
ACE Inhibitor
Increases
Glomerular Filtration Rate
(GFR)
Decreases
Proteinuria
Angiotension II Receptor Blockers
Alternative to
ACE Inhibitor
s
Second-Line Agents
Diuretic
s (especially in
Isolated Systolic Hypertension
)
Third-Line Agents
Beta Blocker
s
Now thought to be a viable option for
Hypertension
control in
Diabetes Mellitus
Historically has been used only when other options have been exhausted
Blunts hypoglycemic response (not seen in studies)
Associated with increased weight gain
Glucose
and lipids less affected with
Carvedilol
Calcium Channel Blocker
s
Non-Dihydropyridine Calcium Channel Blocker
s
Dihydropyridine Calcium Channel Blocker
s
Other Medications
Alpha
Antagonist
s (use only as adjunctive agent)
Management
Algorithm
Gene
ral
See
Hypertension Management
See
Nonpharmacologic Management of Hypertension
See
DASH Diet
Protocol
Start with 2 medications if goal is >20 mmHg lower than current
Blood Pressure
Anticipate needing as many as 3-4
Antihypertensive
s to reach goal
Adjust in specific populations (e.g. Black)
See
Antihypertensives for Specific Populations
May require
ACE Inhibitor
for renal protection, but other agents for
Blood Pressure
control
Step 1: Start with
ACE Inhibitor
or
Angiotensin Receptor Blocker
(ARB)
Proteinuria
present
Evidence supports ACE/ARB as first line
Proteinuria
absent
No evidence for one
Antihypertensive
class over another
Step 2: Add
Diuretic
Serum Creatinine
>1.8:
Loop Diuretic
(e.g.
Furosemide
)
Serum Creatinine
<1.8:
Thiazide Diuretic
Hydrochlorothiazide
Chlorthalidone
(may be preferred)
Longer
Half-Life
(better 24 hour control)
Approaches twice the potency of
Hydrochlorothiazide
Higher risk of
Hypokalemia
Step 3: Add long-acting
Calcium Channel Blocker
Dihydropyridine Calcium Channel Blocker
(e.g.
Norvasc
,
Nifedipine
) or
Non-Dihydropyridine Calcium Channel Blocker
(e.g.
Verapamil
,
Diltiazem
) or
Do not use with
Beta Blocker
Step 4: Add
Beta Blocker
Use caution if
Heart Rate
<70-80 bpm
Avoid if on
Non-Dihydropyridine Calcium Channel Blocker
(e.g.
Verapamil
,
Diltiazem
)
Step 5: Add additional
Antihypertensive
(avoid these agents in the elderly, see
Beers List
)
Central Adrenergic Agonist
(e.g.
Clonidine
)
Alpha Adrenergic Antagonist
(e.g.
Hytrin
)
Reserpine
(very effective per JNC7, but review
Drug Interaction
s)
References
(2003) Diabetes Care 26:S80-2 [PubMed]
Arauz-Pacheco (2004) Diabetes Care 27:S65-7 [PubMed]
Fineberg (1999) Prim Care 26:951-64 [PubMed]
Konzem (2002) Am Fam Physician 66(7):1209-14 [PubMed]
Whalen (2008) Am Fam Physician 78(11): 1277-82 [PubMed]
Type your search phrase here